DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
06 Novembro 2023 - 10:23AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic
stroke, announced today that its third quarter 2023 financial
results will be released after the markets close on Monday,
November 13th. DiaMedica will host a live conference call on
Tuesday, November 14th at 7:00 AM Central Time to provide a
business update and discuss financial results.
Conference Call details:
Date:
Tuesday, November 14, 2023
Time:
7:00 AM CT / 8:00 AM ET
Web access:
https://app.webinar.net/OVpdLmgYMDE
Dial In:
(877) 550-1858
Conference ID:
1754341
Interested parties may access the conference call by dialing in
or listening to the simultaneous webcast. Listeners should log on
to the website or dial in 15 minutes prior to the call. The webcast
will remain available for playback on our website, under investor
relations - events and presentations, following the earnings call
and for 12 months thereafter. A telephonic replay of the conference
call will be available until November 21, 2023, by dialing (800)
645-7964 (US Toll Free) and entering the replay passcode:
2125#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active and clinically studied recombinant
(synthetic) form of the KLK1 protein, an established therapeutic
modality in Asia for the treatment of acute ischemic stroke and
other vascular diseases. For more information visit our website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106951994/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
